Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth

Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet